Ribavirin therapy for severe COVID-19: a retrospective cohort study
- PMID: 32712334
- PMCID: PMC7377772
- DOI: 10.1016/j.ijantimicag.2020.106114
Ribavirin therapy for severe COVID-19: a retrospective cohort study
Abstract
The aim of this study was to compare ribavirin therapy versus supportive therapy only for patients with severe coronavirus disease 2019 (COVID-19). A total of 115 patients with laboratory-confirmed COVID-19 were retrospectively analysed. All patients received supportive care as well as regular laboratory and clinical monitoring. The 115 patients comprised 44 patients who received intravenous ribavirin (treatment group) and 71 who did not (control group). Baseline laboratory and clinical characteristics were similar between the two groups. The negative conversion time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR in the ribavirin group was 12.8 ± 4.1 days compared with 14.1 ± 3.5 days in the control group (P = 0.314). Moreover, 7/41 patients (17.1%) in the ribavirin group died compared with 17/69 (24.6%) in the control group (P = 0.475). Adverse effects were similar between the two groups. In conclusion, in patients with severe COVID-19, ribavirin therapy is not associated with improved negative conversion time for SARS-CoV-2 test and is not associated with an improved mortality rate. Further assessment in designed randomised controlled trials is recommended.
Keywords: 2019 novel coronavirus; COVID-19; Respiratory infection; Ribavirin; SARS-CoV-2; Treatment.
Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Figures
Similar articles
-
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4. Int Immunopharmacol. 2020. PMID: 32889241 Free PMC article. Clinical Trial.
-
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01101-20. doi: 10.1128/AAC.01101-20. Print 2020 Aug 20. Antimicrob Agents Chemother. 2020. PMID: 32631826 Free PMC article. Review.
-
Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study.J Infect Dis. 2020 Aug 17;222(6):910-918. doi: 10.1093/infdis/jiaa388. J Infect Dis. 2020. PMID: 32614392 Free PMC article.
-
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.Clin Microbiol Infect. 2020 Jul;26(7):917-921. doi: 10.1016/j.cmi.2020.04.026. Epub 2020 Apr 25. Clin Microbiol Infect. 2020. PMID: 32344167 Free PMC article.
-
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.J Med Virol. 2020 Jul;92(7):740-746. doi: 10.1002/jmv.25798. Epub 2020 Apr 10. J Med Virol. 2020. PMID: 32227493 Free PMC article. Review.
Cited by
-
The Overview of Potential Antiviral Bioactive Compounds in Poxviruses.Adv Exp Med Biol. 2024;1451:331-336. doi: 10.1007/978-3-031-57165-7_21. Adv Exp Med Biol. 2024. PMID: 38801588 Review.
-
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8. Narra J. 2022. PMID: 38449903 Free PMC article. Review.
-
Coffee as a dietary strategy to prevent SARS-CoV-2 infection.Cell Biosci. 2023 Nov 14;13(1):210. doi: 10.1186/s13578-023-01154-9. Cell Biosci. 2023. PMID: 37964389 Free PMC article.
-
Corticosteroids in COVID-19: pros and cons.Front Med (Lausanne). 2023 Aug 14;10:1202504. doi: 10.3389/fmed.2023.1202504. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37644981 Free PMC article. Review.
-
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.Front Immunol. 2023 Mar 22;14:1147991. doi: 10.3389/fimmu.2023.1147991. eCollection 2023. Front Immunol. 2023. PMID: 37033914 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous